TGen News & Press Releases

Genome sequencing identifies factors that cause resistance to multiple myeloma T cell therapies

Posted Thursday August 31, 2023

Study suggests the problem is more common than previously thought

Erroneous genetic sequences identified for the first time in specific cells of ALS and frontotemporal dementia patients

Posted Wednesday July 19, 2023

Gene splicing defect known as “cryptic exons” detected using single-nuclei RNA sequencing

Novel Genetic Sequencing Technology Helps Researchers Find Answers in Cases of Pediatric Rare Disorders

Posted Monday July 10, 2023

The study identified likely cause of genetic disorder in six families

TGen-led study tracks infection and immunity across the universe of human viruses over time

Posted Monday April 3, 2023

Results offer glimpse into the future of forecasting infection and immunity

Researchers detail changes in the blood-brain barrier related to Alzheimer’s disease

Posted Friday February 24, 2023

The brain tissue grows and accumulates abnormal inflammatory signals

Phone app guides healthy rotation of insulin pumps, sensors

Posted Wednesday January 18, 2023

pilot study tests how type 1 diabetes patients can use app to avoid skin complications

PepSeq Provides Massive Platform for Antibody Analyses

Posted Monday December 5, 2022

Technology developed at TGen described in new study

MindCrowd 2.0 Launches with New Brain Games, Smartphone Access

Posted Wednesday July 20, 2022

One-of-a-kind online study looks for ways to reduce cognitive decline as we age

COVID-19 vaccination activates antibodies targeting parts of virus spike protein shared between coronaviruses

Posted Tuesday July 5, 2022

Technology developed by TGen researchers could help fine-tune future vaccines

Circulating Tumor DNA Guides Chemotherapy Use in Stage II Colon Cancer

Posted Saturday June 4, 2022

Researchers from TGen, a part of City of Hope, contribute to study supporting value of ctDNA in assessing treatment options

Prev
[1]
2
Next

Media Contact

Galen Perry
[email protected]
602-343-8423

Newsletter

News Archive

View Media Release Archive

OnCline

TGen is a partner with OncLive

2023 © All Rights Reserved TGen. Registered 501(c)(3). EIN: 75-3065445